KONTA CHINA (1312.HK)
- Previous Close
0.027 - Open
0.025 - Bid 0.025 x --
- Ask 0.028 x --
- Day's Range
0.025 - 0.028 - 52 Week Range
0.020 - 0.048 - Volume
150,000 - Avg. Volume
1,173,368 - Market Cap (intraday)
156.48M - Beta (5Y Monthly) 0.19
- PE Ratio (TTM)
-- - EPS (TTM)
-0.010 - Earnings Date Mar 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date May 27, 2013
- 1y Target Est
--
Kontafarma China Holdings Limited, an investment holding company, engages in the manufacture and sale of prescription drugs in Mainland China, Singapore, Taiwan, and internationally. It operates in Pharmaceutical Business and Fitness Business segments. The company offers chemical drugs and prescribed traditional Chinese medicines; operates fitness and yoga centers; operates in the franchise business; and provides consultation services for fitness and health activities. It also researches and develops medical products; and offers corporate advisory services. The company was formerly known as Tongfang Kontafarma Holdings Limited and changed its name to Kontafarma China Holdings Limited in September 2022. The company was founded in 1993 and is headquartered in Wan Chai, Hong Kong. Kontafarma China Holdings Limited is a subsidiary of China Health Management Investment Limited.
www.kontafarma.com.hk714
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 1312.HK
View MorePerformance Overview: 1312.HK
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1312.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1312.HK
View MoreValuation Measures
Market Cap
156.48M
Enterprise Value
363.08M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.17
Price/Book (mrq)
0.16
Enterprise Value/Revenue
0.40
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-8.42%
Return on Assets (ttm)
-1.71%
Return on Equity (ttm)
-9.79%
Revenue (ttm)
897.52M
Net Income Avi to Common (ttm)
-75.54M
Diluted EPS (ttm)
-0.010
Balance Sheet and Cash Flow
Total Cash (mrq)
90.58M
Total Debt/Equity (mrq)
30.91%
Levered Free Cash Flow (ttm)
96.43M